{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:05:16Z","timestamp":1777417516891,"version":"3.51.4"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,18]]},"abstract":"<jats:p>Alcohol use disorder (AUD) has become a global public health challenge, with the social and economic costs of alcohol abuse escalating, drawing widespread attention from healthcare professionals and the public worldwide. Particularly in recent years, the COVID-19 pandemic and associated lockdown measures have led to a significant increase in global alcohol consumption, further exacerbating the risk of AUD and sparking in-depth discussions on its prevention and treatment methods. Given that the current mainstay of AUD treatment relies on pharmacotherapy, the aim of this article is to review the progress of existing drug research for the treatment of AUD, and at the same time to focus on drug classes that have not yet been applied to the clinic, but have been shown in recent studies to be potentially exploitable for the treatment of AUD, in order to provide new ideas and directions for future drug research and development efforts.<\/jats:p>","DOI":"10.1097\/md.0000000000040045","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T18:04:24Z","timestamp":1730138664000},"page":"e40045","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Advances in research on medications for the treatment of alcohol use disorders: A review"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7692-3628","authenticated-orcid":false,"given":"Yuzhou","family":"Chen","sequence":"first","affiliation":[{"name":"Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luxin","family":"Zong","sequence":"additional","affiliation":[{"name":"Shandong Daizhuang Hospital, Jining, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qunde","family":"Zhao","sequence":"additional","affiliation":[{"name":"Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3438-0702","authenticated-orcid":false,"given":"Chuanxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Jining Medical University, Jining, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2174\/0929867321666141229103158","article-title":"Alcohol addiction: a molecular biology perspective.","volume":"22","author":"Ferraguti","year":"2015","journal-title":"Curr Med Chem"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"eaax4043","DOI":"10.1126\/sciadv.aax4043","article-title":"Advances in the science and treatment of alcohol use disorder.","volume":"5","author":"Witkiewitz","year":"2019","journal-title":"Sci Adv"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","article-title":"Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders.","volume":"373","author":"Rehm","year":"2009","journal-title":"Lancet (London, England)"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41591-021-01310-z","article-title":"Actionable druggable genome-wide mendelian randomization identifies repurposing opportunities for covid-19.","volume":"27","author":"Gaziano","year":"2021","journal-title":"Nat Med"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1001\/jama.2022.4308","article-title":"Alcohol-related deaths during the covid-19 pandemic.","volume":"327","author":"White","year":"2022","journal-title":"JAMA"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40265-021-01670-3","article-title":"Novel agents for the pharmacological treatment of alcohol use disorder.","volume":"82","author":"Burnette","year":"2022","journal-title":"Drugs"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/YCO.0000000000000512","article-title":"Selecting an appropriate alcohol pharmacotherapy: review of recent findings.","volume":"32","author":"Castr\u00e9n","year":"2019","journal-title":"Curr Opin Psychiatry"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/bcp.12070","article-title":"The clinical pharmacology of acamprosate.","volume":"77","author":"Kalk","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2217\/pgs-2020-0079","article-title":"Pharmacotherapies and personalized medicine for alcohol use disorder: a review.","volume":"21","author":"Lohoff","year":"2020","journal-title":"Pharmacogenomics"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.euroneuro.2013.10.004","article-title":"Pharmacological management of alcohol dependence: from mono-therapy to pharmacogenetics and beyond.","volume":"24","author":"Caputo","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199905133401907","article-title":"Drug therapy for alcohol dependence.","volume":"340","author":"Swift","year":"1999","journal-title":"N Engl J Med"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"e87366","DOI":"10.1371\/journal.pone.0087366","article-title":"Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis.","volume":"9","author":"Skinner","year":"2014","journal-title":"PLoS One"},{"key":"R15-20250503","first-page":"8","article-title":"Topiramate in the treatment of alcohol dependence: a meta-analysis.","volume":"38","author":"Arbaizar","year":"2010","journal-title":"Actas Esp Psiquiatr"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4088\/JCP.08r04062gry","article-title":"Topiramate in the treatment of substance-related disorders: a critical review of the literature.","volume":"71","author":"Shinn","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial.","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet (London, England)"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3389\/fpsyt.2018.00506","article-title":"A review of the potential mechanisms of action of baclofen in alcohol use disorder.","volume":"9","author":"De Beaurepaire","year":"2018","journal-title":"Front Psychiatry"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0000000000001056","article-title":"Efficacy of varenicline in patients with severe alcohol dependence: a pilot double-blind randomized and controlled study.","volume":"39","author":"Pfeifer","year":"2019","journal-title":"J Clin Psychopharmacol"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.","volume":"7","author":"Litten","year":"2013","journal-title":"J Addict Med"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/add.14655","article-title":"A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder.","volume":"114","author":"Kranzler","year":"2019","journal-title":"Addiction"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3109\/09546634.2016.1163315","article-title":"Different doses of gabapentin formulations for postherpetic neuralgia: a systematical review and meta-analysis of randomized controlled trials.","volume":"28","author":"Wang","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders.","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity.","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1001\/archpsyc.55.3.259","article-title":"The effect of depression on return to drinking: a prospective study.","volume":"55","author":"Greenfield","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2012.12.005","article-title":"Adult hippocampal neurogenesis in the pathogenesis of addiction and dual diagnosis disorders.","volume":"130","author":"Chambers","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11065-013-9228-3","article-title":"A role for cognitive rehabilitation in increasing the effectiveness of treatment for alcohol use disorders.","volume":"23","author":"Bates","year":"2013","journal-title":"Neuropsychol Rev"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2021.21030277","article-title":"Adjunctive ketamine with relapse prevention\u2013based psychological therapy in the treatment of alcohol use disorder.","volume":"179","author":"Grabski","year":"2022","journal-title":"Am J Psychiatry"},{"key":"R30-20250503","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.neuropharm.2018.01.017","article-title":"Ketamine for the treatment of addiction: evidence and potential mechanisms.","volume":"142","author":"Ivan Ezquerra-Romano","year":"2018","journal-title":"Neuropharmacology"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1007\/s00213-018-4895-7","article-title":"Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.","volume":"235","author":"Wen","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"R32-20250503","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1021\/acs.jmedchem.3c02087","article-title":"Discovery of 4-ethoxy-6-chloro-5-azaindazoles as novel pde4 inhibitors for the treatment of alcohol use disorder and alcoholic liver diseases.","volume":"67","author":"Zheng","year":"2024","journal-title":"J Med Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:18:51Z","timestamp":1746317931000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":30,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040045","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]}}}